ENDV

 
Common Stock SEC Reporting - Current
OTCQB
Verified Company Profile 5/26/2017
Contact Info
  • 6320 Canoga Avenue
  • 15th Floor
  • Woodland Hills, CA 91367

Business Description


 
Financial Reporting/Disclosure
Reporting Status U.S. Reporting: SEC Reporting
Audited Financials Audited
Latest Report Jun 30, 2017 10-Q
CIK 0001528172
Fiscal Year End 12/31
OTC Marketplace OTCQB
Profile Data
SIC - Industry Classification 2834 - Pharmaceutical preparations
Incorporated In: DE, USA
Year of Inc. 2008
Employees 16 a/o Nov 13, 2012
Company Officers/Contacts
Alan Collier CEO, Interim CFO
Michael Mann President
Don Calabria COO
Steven Barnes SVP, Inv. Rel.
Leonard Makowka Chief Med. Officer
Company Directors
Alan Collier Chairman
Service Providers
Accounting/Auditing Firm
Rose, Snyder & Jacobs
15821 Ventura Blvd.
Suite 490
Encino, 91436
United States
 
Securities Counsel
Frank J. Hariton, Esq.
1065 Dobbs Ferry Road
White Plains, NY, 10607
United States
 
Investor Relations Firm
Regal Consulting LLC
12533 El Camino Real
Unit E
San Diego, CA, 92130
United States
 
Company History
  • Formerly=Hanover Portfolio Acquisitions Inc. until 5-2014
ENDV Security Details
Share Structure
Market Value1 $18,244,878 a/o Oct 19, 2017
Authorized Shares 500,000,000 a/o Oct 06, 2017
Outstanding Shares 289,601,243 a/o Oct 06, 2017
-Restricted 147,395,467 a/o Oct 06, 2017
-Unrestricted 142,205,776 a/o Oct 06, 2017
Held at DTC 134,099,509 a/o Oct 06, 2017
Float 622,092 a/o May 18, 2015
Par Value Not Available
Transfer Agent(s) Verified by Transfer Agent
Equity Stock Transfer
Shareholders
Shareholders of Record 339 a/o Apr 17, 2017
Short Selling Data
Short Interest 124,458 (81.49%)
Sep 29, 2017
Significant Failures to Deliver No

1Market Value calculated only for respective security